Callan Family Office’s MaxCyte MXCT Stock Holding History

Callan Family Office’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$190K	Buy	154,311 +41,322	+37%	+$41.2K	﹤0.01%	1160
2026 Q1	$79.4K	Buy	112,989 +57,867	+105%	+$54K	﹤0.01%	1099
2025 Q4	$85.4K	Buy	+55,122	New	+$88K	﹤0.01%	1080

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Callan Family Office's MXCT Position: Q2 2026 in Review

Callan Family Office increased its MaxCyte (MXCT) stake by 37% in Q2 2026, buying an estimated $41.2K and bringing the position to 154,311 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #1160.

Callan Family Office first reported a position in MXCT in Q4 2025 and has held it in 3 quarters since. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Callan Family Office held 154,311 shares of MaxCyte worth $190K as of Q2 2026.
Callan Family Office bought 41,322 MaxCyte shares in Q2 2026, an estimated $41.2K.
MaxCyte made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1160 holding.
Callan Family Office first reported a position in MaxCyte in Q4 2025 and has held it in 3 quarters since.
122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.